Abivax (AAVXF) Total Non-Current Liabilities (2022 - 2025)

Abivax has reported Total Non-Current Liabilities over the past 4 years, most recently at $77.0 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $77.0 million for Q4 2025, up 1.95% from a year ago — trailing twelve months through Dec 2025 was $77.0 million (up 1.95% YoY), and the annual figure for FY2025 was $74.7 million, down 2.31%.
  • Total Non-Current Liabilities for Q4 2025 was $77.0 million at Abivax, up from $75.5 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for AAVXF hit a ceiling of $77.0 million in Q4 2025 and a floor of $17.2 million in Q4 2022.
  • Median Total Non-Current Liabilities over the past 4 years was $59.5 million (2023), compared with a mean of $53.3 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 151.96% in 2023 and later increased 1.95% in 2025.
  • Abivax's Total Non-Current Liabilities stood at $17.2 million in 2022, then surged by 151.96% to $43.4 million in 2023, then skyrocketed by 73.86% to $75.5 million in 2024, then grew by 1.95% to $77.0 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $77.0 million (Q4 2025), $75.5 million (Q4 2024), and $43.4 million (Q4 2023) per Business Quant data.